2142: HBM Holdings Limited - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

HBM Holdings Limited

HKG:2142

SummaryFactSheetFinancial
Price
HK$10.60
Loss Chance
44.1%
5.46JITTA SCORE
11.09%Over Jitta Line
Jitta Ranking
Biotechnology
6 / 60
Health Care
34 / 233
Hong Kong
?
222 / 2,518
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Essex Bio-Technology Limited
HKG:1061
6.96
HK$2.85
60.19%
3SBio
HKG:1530
7.63
HK$15.68
77.78%
Everest Medicines Limited
HKG:1952
4.59
HK$28.76
21.00%
Mabpharm Private Limited
HKG:2181
n/a
HK$n/a
n/a
Mabpharm Private Limited
HKG:2181
n/a
HK$n/a
n/a
Jitta Factors
Growth Opportunity (63)
Recent Business Performance (97)
Financial Strength (67)
Return to Shareholders (32)
Competitive Advantage (65)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2022
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
5.46
11.09%
3.05
214.76%
3.82
206.24%
Biotechnology
6.96
60.19%
7.63
77.78%
4.59
21.00%
COMPANY DESCRIPTION
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is developing HBM7020 for treating hepatocellular carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance the efficiency of biologics development. The company was incorporated in 2016 and is based in Suzhou, the People’s Republic of China.
www.harbourbiomed.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.